Status:
COMPLETED
The Clareon PanOptix Trifocal IOL: Visual Outcomes and Patient Satisfaction
Lead Sponsor:
Research Insight LLC
Conditions:
Cataract
Eligibility:
All Genders
18+ years
Brief Summary
This will be a single arm, open-label, prospective study of patient-reported outcomes of patients with bilateral implantation of the Panoptix or Panoptix Toric implant.
Detailed Description
The PanOptix trifocal lens by Alcon was introduced in 2015 and is currently in use in over 70 countries. Its outcomes on the AcrySof platform are well documented and highly appealing to patients and c...
Eligibility Criteria
Inclusion
- Patients with cataract and otherwise healthy eyes, not exhibiting any significant ocular morbidity that would be expected to influence outcome measures.
- Patients implanted with Clareon PanOptix or Clareon Panoptix Toric lenses bilaterally within 6 months of the survey administration.
Exclusion
- Patients with visually significant comorbidities (corneal, retina, optic nerve disease) that could affect their satisfaction with surgery
- Patients with surgical complications either during or after surgery (capsule tears, iris trauma, decentered IOL, cystoid macular edema, etc.)
- Patients with previous refractive surgery within the past 6 months prior to cataract surgery
- Patients with \> grade 1 posterior capsule opacity at their last visit
Key Trial Info
Start Date :
June 17 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 10 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05346172
Start Date
June 17 2022
End Date
March 10 2023
Last Update
March 15 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Harvard Eye Associates
Laguna Hills, California, United States, 92653
2
Florida Vision Institute
Stuart, Florida, United States, 34994
3
IllinEye Consulting
Evansville, Illinois, United States, 62025